Femasys Q2 net loss $2.9M; starts FemBloc pivotal trial; appoints COO

FEMASYS INC

2023-Q2 EPS reported -$0.47 revenue$614,498

Q2 net loss $2.9M ($0.22 EPS), revenue $320K (+$17K YoY) from first international sales of $58K.
Cash $10.7M at June 30; expected to fund operations into Q2 2024.
Patient enrollment commenced in FINALE pivotal trial for FemBloc permanent birth control after FDA IDE approval.
Daniel Currie appointed COO with base salary $389K and 40% bonus target.
Received three Health Canada approvals for FemaSeed, FemCerv, FemCath in Q2.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel Currie

Chief Operating Officer

FEMY · FEMASYS INC

Effective: 2023-08-10
Filed: August 10, 2023, 7:59 PM ET

On August 10, 2023, the Company announced that it has designated Daniel Currie, the Company’s Senior Vice President, as its Chief Operating Officer.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

FEMASYS INC reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

announced its financial results for the second quarter ended June 30, 2023 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Currie was appointed as Chief Operating Officer at FEMASYS INC.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On August 10, 2023, the Company announced that it has designated Daniel Currie, the Company’s Senior Vice President, as its Chief Operating Officer.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

FEMASYS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-038917

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.